Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from EyePoint Pharmaceuticals ( (EYPT) ).
On April 13, 2026, EyePoint, Inc. posted an updated investor presentation outlining progress on DURAVYU, an investigational vorolanib intravitreal insert now in Phase 3 trials for wet AMD and DME. The company highlighted that its pivotal wet AMD trials LUGANO and LUCIA are fully enrolled with topline data expected beginning in mid-2026, while the DME Phase 3 COMO and CAPRI trials are anticipated to complete enrollment in the third quarter of 2026.
EyePoint reported more than $220 million in cash and investments as of March 31, 2026, providing runway into the fourth quarter of 2027 and supporting commercial manufacturing scale-up at its Northbridge, Massachusetts facility. Management emphasized DURAVYU’s multi-mechanism tyrosine kinase inhibitor profile, designed for sustained drug release of at least six months and aimed at addressing both VEGF-mediated vascular leakage and IL-6–driven inflammation, positioning the asset to pursue meaningful share in the large anti-VEGF retinal market if late-stage data are successful and regulatory approvals follow.
The most recent analyst rating on (EYPT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, widening losses, and heavy cash burn) and bearish technical signals. Offsetting these are a comparatively solid balance sheet/runway and a favorable earnings-call backdrop driven by Phase 3 progress and defined upcoming data catalysts, while valuation offers limited support due to negative earnings and no dividend.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint, Inc. is a biopharmaceutical company focused on sustained-release drug delivery for retinal diseases, leveraging its Durasert E platform to develop long-acting intravitreal therapies. Its lead investigational product, DURAVYU (vorolanib intravitreal insert), targets major retinal indications including wet age-related macular degeneration (AMD) and diabetic macular edema (DME), markets that together represent more than $15 billion in global branded sales and over 80% of the total branded retinal market.
Average Trading Volume: 1,362,495
Technical Sentiment Signal: Buy
Current Market Cap: $1.18B
See more insights into EYPT stock on TipRanks’ Stock Analysis page.